Identification of a Drug Targeting an Intrinsically Disordered Protein Involved in Pancreatic Adenocarcinoma
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Intrinsically disordered proteins (IDPs) are prevalent in eukaryotes, performing signaling and regulatory functions. Often associated with human diseases, they constitute drug-development targets. NUPR1 is a multifunctional IDP, over-expressed and involved in pancreatic ductal adenocarcinoma (PDAC) development. By screening 1120 FDA-approved compounds, fifteen candidates were selected, and their interactions with NUPR1 were characterized by experimental and simulation techniques. The protein remained disordered upon binding to all fifteen candidates. These compounds were tested in PDAC-derived cell-based assays, and all induced cell-growth arrest and senescence, reduced cell migration, and decreased chemoresistance, mimicking NUPR1-deficiency. The most effective compound completely arrested tumor development in vivo on xenografted PDAC-derived cells in mice. Besides reporting the discovery of a compound targeting an intact IDP and specifically active against PDAC, our study proves the possibility to target the ‘fuzzy’ interface of a protein that remains disordered upon binding to its natural biological partners or to selected drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trott, O., & Olson, A. J. (2010) · Journal of Computational Chemistry · doi:10.1002/jcc.21334 · Cited by 38,412
Tóth, G., Gardai, S. J., Zago, W., Bertoncini, C. W., Cremades, N., Roy, S. L., Tambe, M. A., Rochet, J.-C., Galvagnion, C., Skibinski, G., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087133 · Cited by 151
Cited by
Sohn, B. H., Hwang, J.-E., Jang, H.-J., Lee, H.-S., Oh, S. C., Shim, J.-J., Lee, K.-W., Kim, E. H., Yim, S. Y., Lee, S. H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2211 · Cited by 489
Abian, O., Ortega-Alarcon, D., Jimenez-Alesanco, A., Ceballos-Laita, L., Vega, S., Reyburn, H. T., Rizzuti, B., & Velazquez-Campoy, A. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.07.235 · Cited by 262
Self-citationIs β-Catenin a Druggable Target for Cancer Therapy?
Cui, C., Zhou, X., Zhang, W., Qu, Y., & Ke, X. (2018) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2018.06.003 · Cited by 168
Targeting intrinsically disordered proteins at the edge of chaos
Ruan, H., Sun, Q., Zhang, W., Liu, Y., & Lai, L. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2018.09.017 · Cited by 133
Intrinsically disordered proteins and biomolecular condensates as drug targets
Biesaga, M., Frigolé-Vivas, M., & Salvatella, X. (2021) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2021.02.009 · Cited by 115
“Identifying small molecules stabilizing the structural properties of intrinsically disordered proteins against thermal denaturation has also been used for screening, leading to a compound interacting with NUPR1 that after optimization has shown promising anticancer activity [43,58].”
NUPR1 inhibitor ZZW-115 induces ferroptosis in a mitochondria-dependent manner
Huang, C., Santofimia-Castaño, P., Liu, X., Xia, Y., Peng, L., Gotorbe, C., Neira, J. L., Tang, D., Pouyssegur, J., & Iovanna, J. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00662-2 · Cited by 76
Self-citation
Metadata
- Authors
- Neira, J. L., Bintz, J., Arruebo, M., Rizzuti, B., Bonacci, T., Vega, S., Lanas, A., Velázquez-Campoy, A., Iovanna, J. L., & Abián, O.
- Venue
- Scientific Reports
- Published
- 2017-01-05
- Volume
- 7
- Issue
- 1
- Pages
- 39732-39732
- ISSN
- 2045-2322 (ISSN-L)
- OpenAlex
- W2567785701
- Cited by
- 133
- References
- 2
- FWCI
- 11.97
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.